ZSZeyad T. Sahli

Zeyad T. Sahli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zeyad T. Sahli has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aarti Mathur

    Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

    2 shared publications
  • Joseph K. Canner

    Endocrine Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 606, Baltimore, MD, 21287, USA

    2 shared publications
  • Martha A. Zeiger

    Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    2 shared publications
  • Ahmad Hamad

    Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon

    1 shared publication
  • Ashwyn K. Sharma

    Endocrine Surgery, Department of Surgery, Baltimore, Maryland

    1 shared publication
  • Farah Karipineni

    Endocrine Surgery, Department of Surgery, Baltimore, Maryland

    1 shared publication

Latest Publications

  • Association between age and disease specific mortality in medullary thyroid cancer

    by Zeyad T. Sahli, Joseph K. Canner, Martha A. Zeiger, Aarti Mathur


  • Open Access

    TIRADS Interobserver Variability Among Indeterminate Thyroid Nodules: A Single‐Institution Study

    by Zeyad T. Sahli, Ashwyn K. Sharma, Joseph K. Canner, Farah Karipineni, Osama Ali, Satomi Kawamoto, Jen‐Fan Hang, Aarti Mathur, Syed Z. Ali, Martha A. Zeiger, et al.

    Objectives: A high proportion of cytologically indeterminate, Afirma Gene Expression Classifier “suspicious” thyroid nodules are benign. The Thyroid Imaging Reporting and Data System (TIRADS), was proposed by the American College of Radiology in 2017 to help classify thyroid nodules based on ultrasound characteristics in a standardized fashion to guide management. We aim to determine the interobserver variability of TIRADS classification among cytologically indeterminate and Afirma suspicious nodules.Methods: We retrospectively queried cytopathology archives for thyroid fine‐needle aspiration specimens obtained between February 2012 and September 2016 with associated (1) indeterminate diagnosis, (2) ultrasound imaging at our institution, (3) Afirma suspicious result, and (4) surgery at our institution. We compared the TIRADS variability of the 3 blinded radiologists using intraclass correlation coefficients.Results: Our cohort consisted of 127 nodules. Intraclass correlation coefficients can be interpreted as follows: less than 0.4, poor; 0.4 to 0.59, fair; 0.6 to 0.74, good; 0.75 to 1.00, excellent. The intraclass correlation coefficients of the raw TIRADS score and category variability was 0.561 (95% confidence interval [CI]: 0.464–0.651) or fair and 0.547 (95% CI, 0.449–0.640) or fair, respectively. When analyzing composition, echogenicity, shape, margin, and echogenic foci, the ICCs were 0.552 (95% CI, 0.454–0.643), fair; 0.533 (95% CI, 0.432–0.627), fair; 0.359 (95% CI, 0.248–0.469), poor; 0.192 (95% CI, 0.084–0.308), poor; and 0.549 (95% CI, 0.451– 0.641), fair, respectively.Conclusions: Our results show that among the subset of cytologically indeterminate and Afirma suspicious nodules, TIRADS interobserver variability was fair. Shape and margin criteria were the biggest sources of disagreement. Large prospective studies are needed to evaluate the interobserver variability of TIRADS in this subset of thyroid nodules.


  • Open Access

    Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells

    by Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, Rihab Nasr

    Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt/b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML.